Zobrazeno 1 - 10
of 11
pro vyhledávání: '"François, Donat"'
Autor:
Sue Cheng, François Donat, Pierre Cortez, Ger-Jan Sanderink, Marc Trellu, Emmanuelle Boëlle, Isabelle Paty, Jean-Baptiste Fau
Publikováno v:
British Journal of Clinical Pharmacology. 75:1255-1264
Aim To assess the bioequipotency of equimolar doses of idraparinux (2.5 mg) and idrabiotaparinux (3.0 mg). Method In a phase I study, 48 healthy male volunteers were randomized to a single subcutaneous injection of idrabiotaparinux or idraparinux, fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::532e3040b1060ee1bbc7a57898ea3567
https://doi.org/10.1111/bcp.12009
https://doi.org/10.1111/bcp.12009
Autor:
François Donat, Brigitte Demers, Christine Farenc, Hélène Vermet, Olivier Nicolas, Xavier Boulenc, Eric Sultan
Publikováno v:
Drug Metabolism and Pharmacokinetics. 33:S49
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc354860e1a5507e570a3978a4521b18
https://doi.org/10.1016/j.dmpk.2017.11.169
https://doi.org/10.1016/j.dmpk.2017.11.169
Autor:
François Donat, José Necciari, Jean Pierre Duret, H.N. Magnani, Roger Cariou, Rik de Greef, Alix Santoni
Publikováno v:
Clinical Pharmacokinetics. 41:1-9
Objective: Fondaparinux sodium is the first in a new class of synthetic factor Xa inhibitors that binds reversibly with high affinity to antithrombin III. It has been investigated for the prevention and treatment of arterial and venous thrombotic dis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4548055581a93998f2f20f42189502cb
https://doi.org/10.2165/00003088-200241002-00001
https://doi.org/10.2165/00003088-200241002-00001
Autor:
William Brian, Juan Shi, François Donat, Robert Van Horn, Carolyne Lieu, R.M.E. Vos, John Newton, L. P. C. Delbressine
Publikováno v:
Clinical Pharmacokinetics. 41:19-26
Objective: To investigate the in vitro metabolism of the antithrombotic agent fondaparinux sodium in mammalian liver fractions and to evaluate its potential inhibitory effect on human cytochrome P450 (CYP)-mediated metabolism of other drugs. Methods:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a82f43cd9428c33e875c3ceaf1c9f482
https://doi.org/10.2165/00003088-200241002-00003
https://doi.org/10.2165/00003088-200241002-00003
Publikováno v:
Clinical Pharmacokinetics. 41:11-18
Background: Fondaparinux sodium is a novel antithrombotic agent, the first of a new class of selective factor Xa inhibitors. It has favourable pharmacokinetics including 100% bioavailability, low variability and a mean terminal half-life of 17 hours
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edffbd920fe267474aefc692294defc5
https://doi.org/10.2165/00003088-200241002-00002
https://doi.org/10.2165/00003088-200241002-00002
Autor:
Marc, Trellu, Jean-Baptiste, Fau, Pierre, Cortez, Sue, Cheng, Isabelle, Paty, Emmanuelle, Boëlle, François, Donat, Ger-Jan, Sanderink
Publikováno v:
British journal of clinical pharmacology. 75(5)
To assess the bioequipotency of equimolar doses of idraparinux (2.5 mg) and idrabiotaparinux (3.0 mg).In a phase I study, 48 healthy male volunteers were randomized to a single subcutaneous injection of idrabiotaparinux or idraparinux, followed by pl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0348a3809bb732c7deb6af1351f51426
https://pubmed.ncbi.nlm.nih.gov/23078631
https://pubmed.ncbi.nlm.nih.gov/23078631
Autor:
Francis, Paolucci, Helma, Frasa, Frank, Van Aarle, Anna, Capdevla, Marie-Christine, Clavies, Theo, van Dinther, François, Donat, Yvonne, Hendriks, Michiel, van den Heuvel, Teresa, Nadal, Fabrice, Lagrange, Joseph, Necciari, Yolanda, Perez
Publikováno v:
Clinical laboratory. 49(9-10)
Fondaparinux is a synthetic selective inhibitor of factor Xa recently approved for thromboprophylaxis after major orthopedic surgery. Determination of its concentration gives valuable insight into specific pharmacokinetics or safety studies. The aim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::80303b5e87a329836200787576cad34b
https://pubmed.ncbi.nlm.nih.gov/14572200
https://pubmed.ncbi.nlm.nih.gov/14572200
Publikováno v:
Clinical pharmacokinetics. 41
Objective: Fondaparinux sodium is the first of a new class of antithrombotic agents: the selective factor Xa inhibitors. Coadministration with digoxin may occur in clinical practice and both drugs are excreted almost completely by the renal route. In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f69e3f4f3ddbf3806935059a8e2e58e
https://pubmed.ncbi.nlm.nih.gov/12383044
https://pubmed.ncbi.nlm.nih.gov/12383044
Autor:
José Necciari, Gérald Duc, Maurice Petitou, Jean-François Branellec, Mohamed El Hajji, Eric Garrigou, François Donat, Jean-Marc Herbert, Philippe Duchaussoy, Roger Cariou, Jean Bouthier
Publikováno v:
Seminars in thrombosis and hemostasis. 28(4)
Fondaparinux (Arixtra), a synthetic pentasaccharide, is the first in a new class of antithrombotic agents that selectively inhibit coagulation factor Xa. In vitro experiments demonstrated that it is a selective inhibitor of factor Xa. In plasma, fond
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fbc21bacffa1486fb50f978a0f001f8
https://pubmed.ncbi.nlm.nih.gov/12244487
https://pubmed.ncbi.nlm.nih.gov/12244487
Autor:
Jean-Pierre Bassand, François Donat, Meyer Michel Samama, Roger Cariou, Francois Schiele, Sylvie Fontecave, Nicolas Meneveau, Sophie Claudel, Alain Vuillemenot
Publikováno v:
Thrombosis and haemostasis. 81(2)
Summary Aim of the study. To assess the antithrombotic properties of SR90107/ORG31540, a sulfated pentasaccharide, which enhances specifically antithrombin III mediated inactivation of factor-Xa, in a clinical setting known to promote arterial thromb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62a03fd3e251c0c82217434fb0541d27
https://pubmed.ncbi.nlm.nih.gov/10063994
https://pubmed.ncbi.nlm.nih.gov/10063994